New research from the CWMH.
Following the release of the MGH Perinatal Depression Scale (MGHPDS) on the App Store this past August, we are pleased to announce that the MGHPDS is now available for Android devices on the Google Play store: https://play.google.com/store/apps/details?id=org.womensmentalhealth.mghpds The MGHPDS smartphone app includes digital versions of perinatal depression screening tools including the Edinburgh Postpartum Depression […]
The use of the newer “atypical” or second-generation antipsychotic (SGA) agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. Although most of the women taking atypical antipsychotics are of childbearing age, our information on the reproductive safety of these […]
This week, we have two studies from the Center for Women’s Mental Health — one looking at risk for gestational diabetes in women treated with second generation antipsychotic medications during pregnancy and the other on the use of vortioxetine in perimenopausal women. Ruta Nonacs, MD PhD Gestational Weight Gain and Pre-pregnancy Body Mass Index […]
About 1.4 million people in the U.S. have been diagnosed with ADHD, and about 60-80% of children diagnosed with ADHD will need to take their medication into adulthood. When girls diagnosed in childhood become reproductive-aged women, they face challenging decisions regarding how to proceed with their treatment when they are also family planning. There […]
We are very pleased to announce the release of the MGH Perinatal Depression Scale available free of charge on the App Store (https://appsto.re/us/-3X4jb.i). The MGHPDS smartphone app includes digital versions of perinatal depression screening tools including the Edinburgh Postpartum Depression Scale (EPDS) as well as other instruments which measure relevant symptoms associated with peripartum psychiatric […]
In 2015, we first reported on SAGE-547 (SAGE Therapeutics), a new medication for the treatment of severe postpartum depression. SAGE-547, now called brexanolone, is a new type of antidepressant: a formulation of allopregnanolone, which is an endogenous, naturally occurring neuroactive steroid and a metabolite of progesterone. Data from the most recent study of brexanolone was […]
While we use lithium less commonly now than we have in the past, lithium is still one of the very best mood stabilizers we have. And with regard to its reproductive safety, we have studies going back nearly 50 years. In the 1970s, reports from the International Register of Lithium Babies suggested a […]
Massachusetts General Hospital Efficacy Study Centers on EnBrace HR™ SUNSET, LA (PRWEB) OCTOBER 18, 2016: JayMac Pharmaceuticals is sponsoring a study at Massachusetts General Hospital to assess the efficacy of a pre-and post-natal supplement, EnBrace HR™, as a treatment for the prevention of depression in women with a history of Major Depressive Disorder who decide […]
The use of the newer “atypical” or second-generation antipsychotic agents continues to increase. These medications are used to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and anxiety disorders. Although most of the women taking atypical antipsychotics are of childbearing age, our information on the reproductive safety of these newer […]
Despite the increasing use of the newer “atypical” or second-generation antipsychotic agents to treat a spectrum of psychiatric disorders, including schizophrenia, bipolar disorder, major depression, PTSD and other anxiety disorders, we have relatively little data on the reproductive safety of these newer atypical agents. In response to this deficit, the National Pregnancy Registry for Atypical […]
